Latest
Markets Mojo Market update
News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 1–36
- Matches
- 137
- Sources here
- 20
- Companies here
- 7
Search results
Stored financial headlines
Active search
137 matching headlines
Ticker or company: INTSMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Intensity Therapeutics (Nasdaq:INTS) - Stock Analysis
Intensity Therapeutics (Nasdaq:INTS) is a late-stage clinical biotechnology company focused on developing INT230-6 for cancer treatment. The company recently provided updates on its INVINCIBLE-4 study for triple-negative breast cancer and the INVINCIBLE-3 study for soft tissue sarcoma, with preliminary positive results and plans for …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
Intensity Therapeutics reports Q2 2026 net loss of $3.0M, cash $9.5M; resumes select trial enrollment
Intensity Therapeutics reported a net loss of $3.0 million for Q2 2026 and held $9.5 million in cash. The company resumed limited clinical activities for its INVINCIBLE-3 and INVINCIBLE-4 trials, with preliminary INVINCIBLE-4 data showing promising results in pathological complete response and reduced adverse …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
Earnings call transcript: Intensity Therapeutics misses Q2 2026 EPS as shares slip premarket
Intensity Therapeutics (INTS) reported a wider-than-expected Q2 2026 loss of $1.11 per share, missing analyst estimates by $0.24, causing its shares to fall 4.62% premarket. The clinical-stage biotech is advancing its INVINCIBLE-3 and INVINCIBLE-4 cancer trials, having secured over $23 million in funding over …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
Intensity therapeutics targets INVINCIBLE-4 enrollment completion by end of 2027 while seeking $30M to finish INVINCIBLE-3
Earnings Call Insights: Intensity Therapeutics (INTS) Q2 2026 MANAGEMENT VIEW * "It is my pleasure to provide the latest update of our company's progress in the INVINCIBLE-3 and INVINCIBLE-4 studies, our business development activities, and our plans for the second half of 2026" (Founder, …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
Form 8K Intensity Therapeutics Inc For: 11 August By Investing.com
This article reports that Intensity Therapeutics Inc. filed a Form 8K on August 11, 2026. The Form 8K is a crucial document used by public companies to notify investors of significant events that shareholders should know about. No specific details about the content of …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
INTENSITY THERAPEUTICS, INC. Q2 2026: Net income $(3.0M), EPS $(1.11) — 10-Q Summary
INTENSITY THERAPEUTICS, INC. reported a net loss of $(3.0M) for Q2 2026, an increase from $(2.5M) in Q2 2025, with a diluted loss per share of $(1.11). The company remains pre-revenue but has made progress in its clinical programs, including initiating Phase 3 and …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
Intensity Therapeutics (INTS.US) will release its earnings report on August 11.
Intensity Therapeutics (INTS.US) is scheduled to release its earnings report on August 11. This announcement provides key information about the upcoming financial disclosure for the company. Investors and analysts will be anticipating the report for insights into the company's performance.
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%